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Abstract We have previously shown that PBT-3, a stable
synthetic analog of hepoxilins, inhibits the aggregation of human
platelets in vitro evoked by collagen through inhibition of
thromboxane A2 formation and action on the TP receptor. We
now show that PBT-3 is capable of potently inhibiting the second
phase of aggregation evoked by ADP in both washed human
platelets and platelet-rich plasma (PRP), a phase associated with
thromboxane formation. Aspirin blocks this second phase as
well ; so does the thromboxane receptor antagonist SQ 29,548.
When ADP-evoked aggregation in PRP is activated by heparin
through an enhancement of thromboxane formation, PBT-3,
aspirin as well as SQ 29,548 block this activation through
different mechanisms. These data confirm the inhibitory action of
PBT-3 on aggregation of human platelets through inhibition of
both thromboxane formation and blockade of thromboxane
receptor action and suggest that this family of compounds may be
useful in the treatment of thrombotic disorders in combination
with heparin. ß 2002 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The coagulation system can be modulated by a variety of
factors which are released in vivo and either cause or inhibit
the aggregation of platelets [1]. One of these pathways is the
thromboxane pathway, mediated via the conversion of arachi-
donic acid into thromboxane A2, a potent thrombotic and
vasoconstrictor metabolite [2,3]. Aspirin, an inhibitor of the
formation of thromboxane and other prostanoids, is a ¢rst
line of clinical defense as an anticoagulant but it is not with-
out serious side e¡ects [4^10]. Even heparin, another potent
anticoagulant used clinically to prevent coagulation in indi-
viduals prone to clotting, can sensitize platelets to form
thromboxane A2 and evokes enhanced aggregability of plate-
lets [11]. We report herein that PBT-3, a compound belonging
to a family of hepoxilin analogs, synthesized through modi¢-
cation of natural hepoxilins [12], antagonizes the in vitro ag-
gregation of preparations of washed human platelets and hu-
man platelet-rich plasma (PRP) evoked by ADP. Most
importantly, we demonstrate that the heparin-evoked activa-
tion of platelets can be blocked by PBT-3.
2. Materials and methods
2.1. Materials
PBT-3 was prepared as reported previously [12]. SQ 29,548 was
purchased from the Cayman Chemical Co., Ann Arbor, MI, USA.
Aspirin was from Sigma, St. Louis, MO, USA.
2.2. Preparation of human platelets
Healthy human subjects who had not taken non-steroidal anti-in-
£ammatory agents for at least 2 weeks were used. Blood was drawn
into plastic syringes containing citric acid-sodium citrate^dextrose
(9:1, v/v). It was immediately centrifuged at 23‡C at 200Ug for 15
min. The PRP was either used as such or it was transferred into fresh
plastic tubes and centrifuged at 400Ug for 5 min. The supernatant
was discarded and the platelet pellet was resuspended in fresh medium
(referred to as washed platelets) containing NaCl (137 mM), KCl
(1 mM), NaH2PO4 (0.4 mM), glucose (5.5 mM), HEPES (20 mM)
and CaCl2 (1 mM), pH 7.4, and allowed to stand at room temperature
for 30 min. The platelet count was adjusted to 350U106 cells with
medium or platelet-poor plasma (PPP) to 0.5 ml/assay/cuvette for
each measurement.
2.3. Measurement of platelet aggregation
Appropriate calibration of the platelet aggregometer (PAP-4C) for
0% and 100% transmission was carried out with a sample of platelet
suspension and cell-free medium or PRP and PPP respectively. 0.5 ml
of platelet suspension (PRP or washed platelets) was added to silicon-
ized glass tubes (four samples at a time) and heated with magnetic
stirring (900 rpm) to 37‡C for 1 min in the aggregometer. Either
vehicle alone (ethanol, 1 Wl) or PBT-3, aspirin or SQ 29,548 at various
concentrations in ethanol (1 Wl) was added, followed by ADP 2 min
later. The response was recorded for the next 5 min. In experiments
where PRP was activated with heparin (2.5 Wl of Hepalean (heparin
sodium 1000 U/ml), Organon Teknika, Toronto, ON, Canada), hep-
arin was incubated with PRP for 5 min at 37‡C, then PBT-3 or aspirin
or SQ 29,548 was added and 1 min later, ADP was added. Control
studies in the absence of the three drugs were carried out at the same
time in which 1 Wl of ethanol only was added.
Test compounds were prepared in glass-distilled ethanol (100%) at
the concentrations tested so that the drugs were added in 1 Wl to the
0.5 ml cuvette containing 350U106 platelets.
2.4. Statistical analysis
Values stated are the mean þ S.D. of the number of observations (n)
indicated. Analysis of statistical signi¢cance was performed using Stu-
dent’s t-test involving the Macintosh Statview software program.
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ter; I-BOP, 5-heptenoic acid, 7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-bu-
tenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-,[15-[1K,2K(Z),3L(1E,3S*),4K]] ;
U46619, 5-heptenoic acid, 7-[6-(3-hydroxy-1-octenyl)-2-oxabicyclo-
[2.2.1]-hept-5yl]-[1R-[1K,4K,5L(Z),6K(1E,3S*)]-9,11-dideoxy-9K,11K-
methanoepoxy prostaglandin F2K ; SQ 29,548, [1S-[1a,2a(Z),3a,4a]]-7-
[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]-
hept-2-yl]-5-heptenoic acid
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3. Results and discussion
We report herein that a stable analog of hepoxilins, PBT-3,
antagonizes the aggregation of human platelets evoked by
ADP. Only the second phase of aggregation, caused by
thromboxane A2 generation, is blocked. The same second
phase is blocked by aspirin, due to inhibition of thromboxane
generation, and by SQ 29,548, a selective antagonist of the
thromboxane receptor in platelets [13]. We have demonstrated
these e¡ects in both washed human platelets and in PRP.
The aggregatory e¡ects of ADP and the inhibition of this
e¡ect by PBT-3 are shown in washed human platelets (Fig.
1A). PBT-3 has been shown to act both as a thromboxane
synthase inhibitor [14] and as a thromboxane receptor antag-
onist in platelets, with the latter action more e¡ective than the
former [15]. Fig. 1B shows results of a similar study but using
PRP instead of washed platelets. In PRP unlike in washed
platelets, platelets are activated by heparin [11], and this acti-
vation is associated with thromboxane formation. The hepa-
rin-evoked sensitization of platelets in PRP is blocked by all
three compounds. Note that only the second phase (thrombox-
ane-mediated) is inhibited. This is clearly shown in Fig. 1B.
Aspirin’s e¡ects are mediated via inhibition of thromboxane
generation, those of SQ 29,548 through inhibition of throm-
boxane action at the platelet thromboxane receptor. Fig. 2
shows dose^response curves for all three compounds describ-
ing their inhibition of the heparin-evoked sensitization of PRP
to ADP. This data shows that PBT-3 is quite potent, with an
IC50 = 1.81U1036 M, while that of aspirin is 3.3U1035 M,
but that of the selective thromboxane receptor antagonist
SQ 29,548 is 4.41U1039 M. The enhanced activity of SQ
29,548 over PBT-3 may be due to decreased sequestration of
the former compound to protein. We have shown in a recent
study [15] that PBT-3 antagonized the aggregation in washed
human platelets caused by two thromboxane receptor ago-
nists, I-BOP and U46619, and that PBT-3 antagonized the
binding of 125I-BOP in platelet membranes with an
IC50 = 8U1039 M, just 16-fold less active than I-BOP itself,
and only two-fold less active than U46619.
In summary, the present results demonstrate that PBT-3 is
capable of inhibiting the thromboxane-mediated activation of
platelets sensitized by heparin. The mechanism whereby this
takes place may be through the previously demonstrated ac-
tions of PBT-3 in blocking thromboxane formation and the
thromboxane receptor. Thus, PBT-3 should be considered and
further explored as a new anti-aggregatory drug which may
amplify the actions of heparin as ¢rst line anticoagulant de-
fense by diminishing heparin’s known side e¡ects of thrombo-
cytopenia.
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Fig. 1. Aggregation curves showing the e¡ects of ADP on (A)
washed human platelets and (B) PRP pretreated with heparin. The
stimulatory e¡ects by heparin (2.5 U) of ADP-evoked aggregation
(compare lanes 1 ^ no heparin, and 5 ^ containing heparin) of hu-
man PRP and the inhibitory actions of PBT-3, aspirin and SQ
29,548 on blocking the ADP/heparin e¡ect are shown. All drugs
were added at a dose of 1 Wg (in 1 Wl ethanol) to the cuvettes con-
taining 350U106 platelets in 0.5 ml with the exception of aspirin
which was not active at 1 Wg/ml, and therefore was added at 20 Wg/
ml as shown. All drugs were added 1 min prior to the addition of
ADP which was made within the time period shown by arrows.
Fig. 2. Dose^response curves showing inhibition by PBT-3, SQ
29,548 and aspirin of the ADP-evoked aggregation in heparin-stimu-
lated PRP. IC50 values are shown.
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